AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04221711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive pulsed magnetic stimulation
Description: OMNITRON ProMed is a rPMS (repetitive peripheral magnetic stimulation) device used for deep stimulation of muscles and/or neurones (outside the brain). The energy is delivered by way of a special round treatment coil, whose cover material is tested for biocompatibility.~The OMNITRON ProMed device produces a high-energy impulse field and stimulates tissue, in particular soft tissue, muscles and neurons, by means of repetitive peripheral magnetic stimulation (rPMS). Short, extremely strong magnetic fields in the microsecond range are emitted non-invasively. OMNITRON ProMed works with short-term energy emission at a peak power of up to 60 million watts and a magnetic field strength of up to 100 milliTesla.~The intensity of treatment can be set between 20 and 100 %. The device automatically adjusts the magnetic field strength and the frequency of the pulses emitted depending on the intensity selected.~For comfortable transport and application the product is compact and portable.
Study NCT04221711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Calf Muscle Training for Achilles Tendinopathy
Description: Patients will be asked to stand with their full body weight on the injured leg. From an upright body position and standing with all body weight on the forefoot and the ankle joint in plantar flexion, the calf muscle is then loaded by having the patient slowly lower the heel beneath the forefoot. The calf muscle will only be loaded eccentrically, not concentric. Instead, the non-injured leg is used to get back to the start position. The first set of this exercise is performed in an upright position, followed by a second set with the knee bent to 45°. This regimen is performed 2x per day.~The patients are told to go ahead with the exercise even if they experienced pain. However, they are told to stop if the pain becomes disabling.
Study NCT00753259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AF Clinic
Description: Treatment of atrial fibrillation patients by specialized nurses, supervised by cardiologists, using dedicated software to ensure maximal adherence to AHA/ACC/ESC guidelines on atrial fibrillation treatment
Study NCT01086176 — intervention group
Intervention type: DEVICE
Intervention: NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)
Description: on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference
Study NCT01422668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Khalas dates
Description: every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
Study NCT01422668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Khalas dates
Description: every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
Study NCT04429399 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: decrease the positive end expiratory pressure (PEEP)
Description: decrease the PEEP going from high (according to ExPress Trial) to low level
Study NCT04429399 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mechanical features assessment
Description: evaluation of the mechanical features of respiratory system
Study NCT04429399 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: shunt assessment
Description: evaluation of the pulmonary shunt during two different ventilation setting
Study NCT03966885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.
Study NCT03966885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA)
Description: The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems, and for alcohol and substance misuse. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
Study NCT02032407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Gel
Description: Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
Study NCT03737877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet modification
Description: The parents will have four group sessions with a nutritional therapist, where in depth advice and information about the diet will be provided. Ongoing support will also be provided throughout the study by use of a closed Facebook or WhatsApp group (whichever the parents choose as most appropriate). The diet is based on five main principles:~* Eat at least seven portions of different varieties of fruit and vegetables each day.~* Have a 12 hour overnight break from food (water only during this time).~* Drink a Kefir drink each day - provided free of charge.~* Eat a microbiome friendly, protein rich, breakfast from our menu.~* Reduce sugar and artificial sweeteners.
Study NCT03020017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03020017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03020017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Molecular Therapy
Description: Given NU-0129 IV
Study NCT04868149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)
Description: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed.
Study NCT04868149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)
Description: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed.
Study NCT03143751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl20% (Continuous hyperosmolar therapy)
Description: Early intravenous administration (\<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)~1-hour bolus (15 g if Na+ \< 145 mmol/L; 7.5 g if 145 \< Na+ \< 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+\< 150 mmol/L, reduced to 0.5 g/L if 150 \< Na+ \< 155 mmol/L, Discontinuation when 155 mmol/L\<Na+
Study NCT04159584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Music
Description: Enrolled subjects will undergo 30 minutes of medical music listening
Study NCT04465968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2, IV, day 1
Study NCT04465968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: 80 - 120 mg/day, PO, day 1-14
Study NCT04465968 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent radiotherapy
Description: 66 Gy/33 Fr
Study NCT04465968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.
Study NCT04465968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.
Study NCT04465968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: (For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.~Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.~Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1
Study NCT00541346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Transdermal System
Description: 10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
Study NCT06140459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Toothbrushes
Description: Oral-B Stages 3
Study NCT03432741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given intralesionally
Study NCT03432741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03432741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given intralesionally
Study NCT03432741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given intralesionally
Study NCT03432741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intralesionally
Study NCT03432741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET
Study NCT03432741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given intralesionally
Study NCT03432741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given intralesionally
Study NCT03432741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Given intralesionally
Study NCT03432741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given intralesionally
Study NCT01519453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Asthma Education
Description: 4 home based and 3 phone based sessions with community asthma outreach worker to provide families with asthma education
Study NCT03922451 — intervention group
Intervention type: DRUG
Intervention: piperacillin-tazobactam
Description: Administered for infection treatment or prophylaxis per hospital protocol
Study NCT03922451 — intervention group
Intervention type: DRUG
Intervention: Cefazolin
Description: Administered for infection treatment or prophylaxis per hospital protocol
Study NCT00369551 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo 3-dimensional conformal radiation therapy
Study NCT00369551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT06140459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Toothbrushes
Description: Oral-B Stages 3
Study NCT06140459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsating Toothbrushes
Description: Oral-B Pulsar, Colgate 360º Micro Sonic Power
Study NCT00369551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00369551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00369551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02921048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: omega-3 fatty acids
Study NCT01761656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loading dose atorvastatin
Description: For loading dose atorvastatin intervention, patients will be treated with 80 mg atorvastatin (lipitor) 12 hours before PCI and 40 mg atorvastatin (lipitor) 2 hours before PCI and then 20mg/d after PCI.
Study NCT01761656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional dose atorvastatin
Description: For conventional dose atorvastatin intervention, patients will be treated with 20 mg atorvastatin (lipitor) 12 hours before PCI and then 20mg/d after PCI.
Study NCT00206947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil (5-10 mg/day)
Description: Donepezil will be administered in a dose optimized for treatment, to patients who are stabilized on a ziprasidone treatment
Study NCT00206947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
Study NCT01627054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT7519M
Description: Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
Study NCT00927433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention for cancer-related fatigue
Description: Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions
Study NCT00927433 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Psychoeducational intervention for cancer-related fatigue
Description: Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions
Study NCT02036502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study NCT02036502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral capsule
Study NCT02036502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet IV infusion
Study NCT06140459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsating Toothbrushes
Description: Oral-B Pulsar, Colgate 360º Micro Sonic Power
Study NCT01306656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10,000 IU Vitamin D3
Description: Month 1: 20,000 IU vitamin D3 once a week~Months 2-6: 10,000 IU vitamin D3 once a week
Study NCT01306656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Month 1: Placebo once a week~Months 2-6: Placebo once a week
Study NCT01306656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Daily multivitamin with 400 IU vitamin D.
Study NCT01306656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Daily multivitamin with 400 IU vitamin D.
Study NCT01570049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: for injection
Study NCT03344627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem standard dose
Description: * Empirical with 1 g meropenem intravenous infusion in 30 minutes then 1 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection.
Study NCT03344627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem high dose
Description: * Empirical with 2 g meropenem intravenous infusion in 30 minutes then 2 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection
Study NCT01321957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, 5FU/LV, Bevacizumab
Description: bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
Study NCT01321957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
Description: bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
Study NCT03046225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: TENS was applied in the conventional mode, through two self-adhesive electrodes of size 5x9cm positioned parallel to the lumbar spine, on the nerve roots of L3, L4 and L5, with frequency of 100 Hz and pulse duration of 100 μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was gradually increased, with his permission, during the application time.
Study NCT02036502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: IV infusion
Study NCT02608554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taichi
Description: The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.
Study NCT02608554 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitored exercise
Description: Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
Study NCT03021850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility training with or without different thermal modalities
Description: Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
Study NCT04022876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered IV on Day 1 of every 21-day cycle.
Study NCT03021850 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flexibility training with or without different thermal modalities
Description: Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
Study NCT04416087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Positron emission tomography (PET) imaging at rest and during supine bicycle exercise Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
Study NCT01821534 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No treatment (intervention) was administered.
Study NCT02101047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Study NCT03968302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM A Triple therapy for helicobacter pylori
Description: The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
Study NCT03968302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM B Quadruple therapy for helicobacter pylori
Description: Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
Study NCT02786628 — intervention group
Intervention type: OTHER
Intervention: Physical performance testing and patient-generated health data
Description: All patients will complete cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant) and wear a Fitbit Charge HR for the duration of one cycle of chemotherapy.
Study NCT00753259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual
Description: Routine clinical care of atrial fibrillation patients, provided by cardiologists, without the help of specialized nurses or dedicated software.